Literature DB >> 31673959

Outcomes of endovascular treatment in acute ischemic stroke patients with current malignancy.

Bang-Hoon Cho1, Woong Yoon2, Joon-Tae Kim3, Kang-Ho Choi3, Kyung-Wook Kang3, Jin-Heui Lee3, Ki-Hyun Cho3, Man-Seok Park4.   

Abstract

BACKGROUND AND PURPOSES: The role of endovascular recanalization in the treatment of cancer patients with acute stroke remains elusive. Our study aimed to investigate the clinical and imaging outcomes of endovascular recanalization treatment in patients with acute large vessel occlusion stroke who had active cancer.
METHODS: We retrospectively reviewed the data from our stroke registry from January 2011 to September 2016 which was collected prospectively. Acute stroke patients with large artery occlusion in the anterior circulation who had active cancer were identified. Baseline clinical characteristics and postprocedural and long-term clinicoradiological outcomes were evaluated. A good outcome was defined as a 90-day modified Rankin Scale score of 0 to 2. Outcomes were also compared with those of non-malignancy patients who had received endovascular therapy during the same period.
RESULTS: A total of 378 ischemic stroke patients received endovascular treatment, of whom 27 (7.14 %) had current malignancy. In patients with current malignancy, a low baseline NIHSS score and male sex were associated with functional independency at 90 days. When comparing with non-malignancy patients, no significant differences in the proportions of patients with symptomatic intracranial hemorrhage (11.1% vs 16.2%, p = 0.60) and good functional outcome (37.0% vs 39.6%, p = 0.84) were found in the malignancy patients.
CONCLUSION: Endovascular treatment might be a feasible therapeutic option for acute ischemic stroke patients with current malignancy when candidates are selected carefully because the outcomes were not differed. Future large-scale prospective studies are necessary.

Entities:  

Keywords:  Acute ischemic stroke; Current malignancy; Endovascular treatment; Outcome

Mesh:

Substances:

Year:  2019        PMID: 31673959     DOI: 10.1007/s10072-019-04103-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  6 in total

Review 1.  Endovascular treatment in patients with acute ischemic stroke and cancer: Systematic review and meta-analysis.

Authors:  Danilo Caimano; Federica Letteri; Francesco Capasso; Nicola Limbucci; Patrizia Nencini; Cristina Sarti; Fana Alemseged; Guido Bigliardi; Andrea Morotti; Danilo Toni; Andrea Zini; Francesco Arba
Journal:  Eur Stroke J       Date:  2022-06-02

Review 2.  Cancer and stroke: commonly encountered by clinicians, but little evidence to guide clinical approach.

Authors:  Malin Woock; Nicolas Martinez-Majander; David J Seiffge; Henriette Aurora Selvik; Annika Nordanstig; Petra Redfors; Erik Lindgren; Mayte Sanchez van Kammen; Alexandros Rentzos; Jonathan M Coutinho; Karen Doyle; Halvor Naess; Jukka Putaala; Katarina Jood; Turgut Tatlisumak
Journal:  Ther Adv Neurol Disord       Date:  2022-06-28       Impact factor: 6.430

3.  Effectiveness of mechanical thrombectomy in cancer-related stroke and associated factors with unfavorable outcome.

Authors:  Eung-Joon Lee; Jeonghoon Bae; Hae-Bong Jeong; Eun Ji Lee; Han-Yeong Jeong; Byung-Woo Yoon
Journal:  BMC Neurol       Date:  2021-02-06       Impact factor: 2.474

Review 4.  Mechanical Thrombectomy for Acute Ischemic Stroke in Patients with Malignancy: A Systematic Review.

Authors:  Athina-Maria Aloizou; Daniel Richter; Jeyanthan Charles James; Carsten Lukas; Ralf Gold; Christos Krogias
Journal:  J Clin Med       Date:  2022-08-11       Impact factor: 4.964

Review 5.  Cancer-related stroke: Exploring personalized therapy strategies.

Authors:  Yu-Jie Chen; Rui-Guo Dong; Meng-Meng Zhang; Chao Sheng; Peng-Fei Guo; Jie Sun
Journal:  Brain Behav       Date:  2022-08-08       Impact factor: 3.405

6.  Prognosis of Acute Ischaemic Stroke Patients with Cancer: A National Inpatient Sample Study.

Authors:  Tiberiu A Pana; Mohamed O Mohamed; Mamas A Mamas; Phyo K Myint
Journal:  Cancers (Basel)       Date:  2021-05-03       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.